Literature DB >> 14610182

Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase.

Shixing Tang1, Tsutomu Murakami, Naiqian Cheng, Alasdair C Steven, Eric O Freed, Judith G Levin.   

Abstract

We previously described the phenotype associated with three alanine substitution mutations in conserved residues (Trp23, Phe40, and Asp51) in the N-terminal domain of human immunodeficiency virus type 1 capsid protein (CA). All of the mutants produce noninfectious virions that lack conical cores and, despite having a functional reverse transcriptase (RT), are unable to initiate reverse transcription in vivo. Here, we have focused on elucidating the mechanism by which these CA mutations disrupt virus infectivity. We also report that cyclophilin A packaging is severely reduced in W23A and F40A virions, even though these residues are distant from the cyclophilin A binding loop. To correlate loss of infectivity with a possible defect in an early event preceding reverse transcription, we modeled disassembly by generating viral cores from particles treated with mild nonionic detergent; cores were isolated by sedimentation in sucrose density gradients. In general, fractions containing mutant cores exhibited a normal protein profile. However, there were two striking differences from the wild-type pattern: mutant core fractions displayed a marked deficiency in RT protein and enzymatic activity (<5% of total RT in gradient fractions) and a substantial increase in the retention of CA. The high level of core-associated CA suggests that mutant cores may be unable to undergo proper disassembly. Thus, taken together with the almost complete absence of RT in mutant cores, these findings can account for the failure of the three CA mutants to synthesize viral DNA following virus entry into cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610182      PMCID: PMC262599          DOI: 10.1128/jvi.77.23.12592-12602.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex.

Authors:  C M Farnet; W A Haseltine
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

2.  HIV: early virus-cell interactions.

Authors:  C Grewe; A Beck; H R Gelderblom
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

3.  Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.

Authors:  K Wiegers; G Rutter; H Kottler; U Tessmer; H Hohenberg; H G Kräusslich
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein.

Authors:  T R Gamble; S Yoo; F F Vajdos; U K von Schwedler; D K Worthylake; H Wang; J P McCutcheon; W I Sundquist; C P Hill
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

5.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

6.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly.

Authors:  U K von Schwedler; T L Stemmler; V Y Klishko; S Li; K H Albertine; D R Davis; W I Sundquist
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

9.  Cyclophilin A-induced alterations of human immunodeficiency virus type 1 CA protein in vitro.

Authors:  B E Agresta; C A Carter
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

10.  Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing.

Authors:  R L Willey; T Klimkait; D M Frucht; J S Bonifacino; M A Martin
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

View more
  37 in total

Review 1.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  A new functional role of HIV-1 integrase during uncoating of the viral core.

Authors:  Marisa S Briones; Samson A Chow
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  The matrix protein of human immunodeficiency virus is cleaved and packed into virion cores.

Authors:  A G Bukrinskaya; G K Vorkunova; M E Burshtein; M Stevenson
Journal:  Dokl Biol Sci       Date:  2006 May-Jun

4.  Effects of rapid antigen degradation and VEE glycoprotein specificity on immune responses induced by a VEE replicon vaccine.

Authors:  M E Fluet; A C Whitmore; D A Moshkoff; K Fu; Y Tang; M L Collier; A West; D T Moore; R Swanstrom; R E Johnston; N L Davis
Journal:  Virology       Date:  2007-09-27       Impact factor: 3.616

5.  Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix.

Authors:  Ajay K Bhatia; Nancy Campbell; Antonito Panganiban; Lee Ratner
Journal:  Virology       Date:  2007-08-13       Impact factor: 3.616

6.  RSV capsid polymorphism correlates with polymerization efficiency and envelope glycoprotein content: implications that nucleation controls morphogenesis.

Authors:  Carmen Butan; Dennis C Winkler; J Bernard Heymann; Rebecca C Craven; Alasdair C Steven
Journal:  J Mol Biol       Date:  2007-12-08       Impact factor: 5.469

7.  Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly.

Authors:  Katrina J Heyrana; Boon Chong Goh; Juan R Perilla; Tam-Linh N Nguyen; Matthew R England; Maria C Bewley; Klaus Schulten; Rebecca C Craven
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

8.  The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release.

Authors:  Daniel Melamed; Michal Mark-Danieli; Michal Kenan-Eichler; Osnat Kraus; Asher Castiel; Nihay Laham; Tal Pupko; Fabian Glaser; Nir Ben-Tal; Eran Bacharach
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle.

Authors:  Sook-Kyung Lee; Janera Harris; Ronald Swanstrom
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail.

Authors:  Ajay K Bhatia; Rajnish Kaushik; Nancy A Campbell; Suzanne E Pontow; Lee Ratner
Journal:  Virology       Date:  2008-12-06       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.